Alvotech and Fuji Pharma are entering into an exclusive partnership for the commercialization by Fuji Pharma of Alvotech’s biosimilar portfolio in Japan.   Alvotech will be responsible for development and supply of multiple high value biosimilar assets from its current product pipeline, while Fuji Pharma will be responsible for registration and commercialization of these assets in Japan. Alvotech’s biosimilar portfolio includes high value products used in advanced therapies of oncology, ophtha...